Video

The Aftermath of Hepatitis C Drugs on Specialty Spending

Author(s):

Davy James, Managing Editor

David Lassen, chief clinical officer at Prime Therapeutics, discusses how high cost hepatitis C drugs have impacted the entire specialty landscape.

David Lassen, chief clinical officer at Prime Therapeutics, discusses how high cost hepatitis C drugs have impacted the entire specialty landscape.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com
Related Content
Cardiomyopathy (ATTR-CM) -- Image credit: Dzmitry | stock.adobe.com
July 1st 2025

Pharmacists Have a Crucial Role Helping Patients With ATTR-CM Navigate Treatment With Tafamidis

Gillian McGovern, Associate Editor Jennifer Goldman, PharmD, CDES, BC-ADM, FCCP
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
In Control Room Doctor and Radiologist Discuss Diagnosis while Watching Procedure and Monitors Showing Brain Scans Results, In the Background Patient Undergoes MRI or CT Scan Procedure.
June 27th 2025

Chronic IVIG Therapy May Reduce Incidence of Cancer, Especially in Patients With CIDP

Luke Halpern, Assistant Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Water coming from a faucet - Image credit: Ajax9 | stock.adobe.com
June 25th 2025

Is Fluoride Friend or Foe?

Jim Ruble, PharmD, JD
Pediatric multisystem inflammatory syndrome. kawasaki disease symptoms.
June 23rd 2025

IVIG-Glucocorticoid Combination Therapy Reduces Need for Adjunctive Immunotherapy in Pediatric MIS-C

Luke Halpern, Assistant Editor